A drug-free pill for sustained appetite suppression.

Meet Sirona — a once daily hydrogel pill that gently expands in the stomach to create a sustained feeling of fullness, helping reduce calorie intake without medication.

Mechanism of action

How Sirona works, step by step

A simple daily routine — no drugs, no surgery, no injections.

01
Taken once daily

Taken once daily

Sirona is taken once daily as a convenient oral pill — part of your normal routine.

02
Sustained satiety

Sustained satiety

Once in the stomach, Sirona expands to reduce available volume and stays for several days — providing sustained appetite suppression that reduces calorie intake.

03
Passes naturally

Passes naturally

Sirona then breaks into smaller pieces that are excreted naturally, just like food.

Clinical evidence

Proven across two clinical trials

Sirona's effect on appetite and weight has been studied in two UK clinical trials, with more than 9,500 pills dosed. The headline results are now published in the peer-reviewed journal Obesity.

~400kcal
fewer calories consumed per day vs. placebo
6.4%
total body weight lost at 24 weeks in individuals with Class 1 obesity
9,500+
pills dosed across two clinical trials
Excellent
safety & tolerability profile demonstrated

Change in mean daily calorie intake

Change from baseline at 24 weeks · kcal
Sirona Placebo
400 200 0 −200 −400 −600 Sirona Placebo kcal change from baseline

Bars show mean change from baseline; whiskers indicate variability. Participants on Sirona consumed ~400 fewer calories per day than those on placebo.

Total body weight loss over time

Mean % change from baseline
Class 1 obesity (Sirona) Placebo
0% −1% −2% −3% −4% −5% −6% −7% −8% −1.0% −6.4% 1 5 12 24 Weeks Mean % total body weight loss

Individuals with Class 1 obesity on Sirona reached −6.4% total body weight loss at 24 weeks; placebo reached −1.0% at 12 weeks. Whiskers indicate variability.

Read the published results in Obesity Peer-reviewed in Obesity (Wiley), 2025. DOI: 10.1002/oby.70066
Who is Sirona for?

Three target markets Sirona was designed for

01
BMI 25–30

Individuals living with overweight

Many people in this range aren't eligible for GLP-1 therapies like Wegovy and Mounjaro, and don't need their intensity. Sirona is an early intervention to help return to a healthy weight and prevent progression into obesity.

02
Drug-free choice

An alternative to anti-obesity medications

A treatment option for people who cannot, or simply prefer not to, use pharmacotherapy for their weight loss — without injections or systemic drugs.

03
Maintaining weight loss

Support post anti-obesity medication

Sirona is uniquely positioned to support people transitioning off anti-obesity medications (e.g. GLP-1s), helping to minimise weight regain and maintain their new weight long term.

In their words

But don't just take our word for it

Real experiences from participants across our UK clinical trials.

I have lost weight & feel like I have control over what I eat.

UK clinical trial participant

Great weight loss without [the] psychological battle with my brain and body.

UK clinical trial participant

I felt less hungry… I had to make an effort to eat.

UK clinical trial participant
Regulatory Affairs

Built to medical-device standards

Sirona has completed its second UK clinical trial and is pending regulatory approval in Europe. It is manufactured in OMP's own ISO 13485 and ISO 9001 certified facility.

Manufacturing quality
ISO 13485Medical devices
ISO 9001Quality management
Approval pathway
First UK clinical trialCompleted
First-in-human evaluation of the hydrogel platform.
Second UK clinical trialCompleted
Randomised placebo controlled trial (RCT).
European regulatory approvalIn review
CE marking currently under assessment.
IFU availableOn CE approval
Instructions for Use published for download.
Instructions for Use (IFU)Available here once CE mark has been approved.
Coming soon

Interested in Sirona?

For partnership, clinical or media enquiries, our team would love to hear from you.

Our collaborators